Etrasimod Results Justify Pfizer’s Leap Of Faith In Arena Buyout
Big Pharma Executed $6.7bn Deal Without Seeing Phase III Data
Detailed data presented at Digestive Disease Week show competitive efficacy in ulcerative colitis and a potential best-in-class safety profile for the S1P receptor modulator Pfizer acquired earlier this year.
